Featured Articles

31. Disclosure Management System: Build Or Buy? 6/19/2025

    Clinical trial disclosure regulations are tightening worldwide. In order to maintain compliance, sponsors must determine whether to build an internal disclosure management system or buy a solution.

32. New Data Sources Can Help Pharma Meet Challenges 6/19/2025

    Claire Riches, Citeline VP of Clinical Solutions, discussed the changing pharma landscape and data options, such as RWD, RWE, and AI at Citeline Elevate Spring 2025.

33. Completed Clinical Trials Continued To Climb In 2024 6/19/2025

    Data collected in this report reflects a shift toward sustained growth, reflecting rapid advancement in therapeutic areas such as oncology, autoimmune/inflammation, and central nervous system studies.

34. Overcoming Patient Recruitment Challenges With RWD 4/28/2025

    Complex I/E criteria? Seeking broad demographic representation? Don’t know where to find eligible patients? No problem! See how comprehensive data and a connected ecosystem combine to revamp recruitment.

35. The Future Of Patient Recruitment: Leveraging RWD For Precision 4/25/2025

    To combat the costly challenges of patient recruitment and keep trials on track, sponsors can leverage real-world data.

36. Unlocking The Potential of RWD In Clinical Trial Recruitment 4/25/2025

    Insights derived from real-world data can be used not only to identify potential patients for participation in clinical research, but also to inform the overall patient engagement and retention strategy of a clinical trial.

37. Overcoming Complex Patient Recruitment Challenges With Data 4/15/2025

    Overcome roadblocks to recruiting patients for rare disease clinical trials with RWD and RWE, including lack of diagnosis and stringent I/E criteria, geographic dispersion, and high dropout rates.

38. Global Trial Disclosure Landscape Grows Increasingly Complex 4/15/2025

    The industry is witnessing a global trend toward increased transparency and more stringent enforcement of clinical trial reporting requirements. However mechanisms and penalties differ significantly across regions and countries.

39. A Dip In NAS Launches Annual Review 2025 Supplement 4/15/2025

    Even though new active substance (NAS) launches declined 11% in 2024, this still represented the fourth-highest total of newcomers to the pharma runway recorded and predictions remain good for 2025.

40. Life Sciences Companies Talk Past, Present, And Future At JPM 3/21/2025

    The 43rd annual J.P. Morgan Healthcare Conference featured presentations from a host of large, medium, and small-cap life sciences companies that discussed past performance and future outlooks.